Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Neuphoria Therapeutics Inc. (NEUP) had Return on Tangible Equity of -3.10% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-0.51M |
|
-- |
|
-- |
|
$1.21M |
|
$-1.21M |
|
$0.67M |
|
$-0.54M |
|
$-0.54M |
|
$-0.51M |
|
$-0.51M |
|
$-0.51M |
|
$-0.51M |
|
$-1.21M |
|
$-1.05M |
|
5.41M |
|
5.41M |
|
$-0.09 |
|
$-0.09 |
|
| Balance Sheet Financials | |
$21.66M |
|
-- |
|
$13.15M |
|
$34.81M |
|
$1.51M |
|
-- |
|
$3.87M |
|
$5.39M |
|
$29.42M |
|
$16.27M |
|
$29.42M |
|
5.38M |
|
| Cash Flow Statement Financials | |
$-13.57M |
|
-- |
|
$17.92M |
|
$14.29M |
|
$19.44M |
|
$5.15M |
|
$0.28M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.31 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-1.72% |
|
|
Return on Tangible Equity |
-3.10% |
-1.45% |
|
-1.72% |
|
$5.47 |
|
$-2.51 |
|
$-2.51 |
|